20 Truths About Tumor Treating Fields Mesothelioma: Busted
Tumor Treating Fields Mesothelioma
Tumor treating mesothelioma from fields is a new type of therapy that makes use of alternating electrical fields to limit cancer growth. It is combined with chemotherapy to treat mesothelioma pleural.
Following the success of the STELLAR study, the FDA approved TTFields together with pemetrexed-cisplatin. in the year 2019. FDA approved TTFields. Patients are able to ask their mesothelioma doctor to prescribe this treatment.
Disrupting Cell Division
TTFields uses alternating electrical fields that disrupt cancer cell protein and prevent the cells from multiplying. This can stop mesothelioma from expanding or growing in other organs. The TTFields can also stimulate the production of proteins that can destroy cancerous cells and help the immune system fight mesothelioma tumors.
During treatment, patients wear a small device that has pads that are insulated and adhere to the skin. The device delivers low-intensity electric current, and patients can regulate the amount of treatment they receive. A mesothelioma session lasts about 30 minutes. Patients can receive TTFields treatment multiple times a day.
A TTFields 2021 study showed that electrical fields of between 100 and 300 kilohertz were able to stop the growth of cancer cells and trigger their death. The study examined different kinds of cancerous cells, and found that electrical fields killed all of them, regardless of the cellular structure.
The study's author suggested the use of TTFields with chemotherapy for mesothelioma. Novocure's TTFields product, NovoTTF-100L was approved by the FDA in the year 2019 to treat pleural mesothelioma that is not resectable. It is now available through mesothelioma specialists at medical centers across the U.S., including the West Cancer Center in Memphis. The NovoTTF 100L device, also known as Optune Lua has been used in the treatment of mesothelioma in combination with platinum-based chemotherapy and pemetrexed. Mesothelioma patients have reported extended survival time when the TTFields treatment is combined with chemotherapy.
Another study, published in "Lung Cancer", reported that TTFields therapy is highly effective in conjunction with chemotherapy. In the study researchers found that combining chemotherapy and TTFields reduced the amount of malignant mesothelioma cells in animals by more than 80 percent. The study also demonstrated that combination treatments can increase the production of proteins that kill mesothelioma cancer cells and reduce the amount of cancerous DNA in your body.
Despite being an emerging treatment, many mesothelioma doctors do not offer TTFields to treat pleural mesothelioma. Patients may still be able to access this treatment through clinical trials or at Novocure-certified mesothelioma clinics.
Stalling Tumor Development
Mesothelioma forms when mesothelial cells alter and exceed their normal lifespan, leading to an overabundance of cancerous cells that multiply and spread throughout the body. Tumor treating fields stop mesothelioma tumors from advancing and spreading by stopping mesothelial cells from replicating.
The TTFields device is worn on the chest like the vest, and creates a series of electrical fields that alter proteins, kill cancer cells, and slow down the growth of tumors. The device is fitted with insulated pads that adhere to the skin. Patients or health professionals are able to apply them at home.
Doctors suggest mixing TTFields with chemotherapy to get the greatest results. The combination increases the production of proteins that destroy cancer cells and reduces the capacity of cancer cells to repair DNA damage caused by chemotherapy drugs. This allows the chemotherapies to work harder and increase survival rates in mesothelioma.
In the STELLAR trial, which was conducted in 2017, TTFields therapy, when combined with chemotherapy significantly increased survival for mesothelioma patients. The FDA approved the NovoTTF-100L System and is now marketed as Optune Lua, for use in conjunction with pemetrexed, carboplatin and cisplatin as a first-line treatment for malignant unresectable pleural mesothelioma in 2019.
Researchers have discovered that the TTFields treatment is effective against mesothelioma by stopping cell division. The TTFields therapy causes cancer cells to split through a process called mitosis. The cellular debris then gets trapped in the surrounding tissues and hinders the growth of new tissue. Mitosis prevents mesothelioma cancer cells from healing damaged genetic material and makes them more sensitive to radiation treatment.
The TTFields treatment is also able to reduce the flow of blood to tumors by suppressing vascular endothelial growth factor, also known as VEGF, and by increasing hypoxia-inducible factor-1 beta, or HIF-1a, which is linked with cancer cell angiogenesis.
Speak to your doctor when you've been diagnosed mesothelioma. Many mesothelioma specialists are working with Novocure on clinical trials to evaluate the efficacy of this revolutionary treatment. Contact a Novocure certified specialist at one of the more than 1,300 U.S. Treatment Centers to learn more about mesothelioma treatment with TTFields.
Killing Tumor Cells
Tumor treating fields for treating tumors (TTFields), which send electrical waves throughout the body to disrupt cell division and eliminate cancer cells. TTFields are low intensity and intermediate frequency electrical fields that alternatingly are targeted at cancerous cells, without harming healthy cells. They also hinder DNA repair and enhance cell defenses, making it more difficult for cancerous cells to survive. TTF is a non-invasive treatment and has very few side effects besides minor skin irritation.
Scientists believe TTFields are responsible for preventing mitosis, a process by which cells divide into two identical new cells. Normal cells have control mechanisms in place to limit the rate of mitosis, but malignant cancerous cells breach this control and multiply at a runaway pace. TTFields interferes with this process by blocking signals that regulate the rate of growth in mesothelioma tumor cells. In the STELLAR study, TTFields when combined with chemotherapy significantly increased survival rates for mesothelioma patients. Mesothelioma patients who received TTFields in addition to maintenance cycles of chemotherapy were able to live on average six months longer than patients receiving only chemotherapy.
A separate research study also found that TTFields can boost the effectiveness of certain chemotherapy drugs, called platinum-based therapies. These platinum-based treatments eliminate mesothelioma cells by targeting mitochondria, which is the source that cancerous cells derive their energy. When TTFields is combined with chemotherapies, the combination can result in higher levels DNA damage and faster death of cancer cells.
In some cases, TTFields also increase the effects of radiation therapy. Scientists have noted that when you combine TTFields and radiation therapy can create the "synergistic" effect. This means that the combination treatment increases the sensitivity of cancer cells to radiation.
At present, TTFields can only be available at certain mesothelioma clinics. However, a mesothelioma specialist can determine whether you may be eligible for this treatment. If you qualify an attorney for mesothelioma can assist you in obtaining treatment that includes TTFields along with chemotherapy. A mesothelioma lawyer can assist veterans access VA-covered treatments.
Side Effects
The TT fields therapy disrupts cancer cells by generating an electrical field that interferes with the cell's ability to divide. This could slow down the growth of tumors and stop the spread of cancer to other parts of the body. The TT Fields device isn't invasive. It does not cause discomfort or damage to surrounding tissue. This is different than conventional chemotherapy, which requires intravenous injections or radiation both of which could cause severe side effects.
In an investigation, patients who received a combination of TT fields and temozolomide experienced survival improvements similar to those who were treated with chemo on their own. Doctors attributed the improved survival to TT fields' ability to increase the effectiveness of chemo and lessen the risk of the adverse effects.
Mesothelioma cancer cells can transform into cancerous cells and replicate uncontrollably to form tumors that infiltrate the organs of your body. Mesothelioma treatment like TT fields stops mesothelioma from reproducing and inhibiting the body's normal functions by stopping cell division.
During a mesothelioma trial patients with mesothelioma who received TT fields in conjunction with their chemo had an average survival of 18.2 months. Those who received TT fields, but not chemotherapy had a survival rate of 12.1.
Tumor-treating fields can be applied to the pleura, or the thin lining that covers your lungs, either on your chest or abdominal wall. The device is small enough to be worn up to 18 hours a day, even during sleep. Patients are able to continue their daily lives and work while undergoing treatment.
mesothelioma treatment options can be incorporated with traditional chemotherapy or immunotherapy as well as other mesothelioma treatments. Mesothelioma patient interested in TT should discuss the possibility with their physician. They can explain the conditions for eligibility and the potential benefits for each patient's case.